The communication regarding the issuance or sale of securities in the investment sector is subject to strict regulations. Only individuals classified as "Relevant Persons" are allowed to receive invitations or inducements to engage in these activities. This classification is crucial as it determines who can legally participate in investment opportunities.
Compliance with regulations is highly important in the financial services sector, especially under the Financial Services and Markets Act 2000.
Investors should be cautious as engaging in the discussed investments may involve significant risks, including the potential loss of the entire investment. Therefore, it is advisable for individuals considering such investments to consult authorized professionals specializing in investment advice. Seeking advice from professionals is essential to navigate the complexities and risks associated with securities investments.
The target market for the offered securities is limited to professional clients and eligible counterparties, as outlined by MiFID II and UK MIFIR product governance regulations. It is important to understand that the assessment of the target market does not determine suitability or appropriateness for investment purposes. Each distributor is responsible for conducting its own analysis to determine the appropriate distribution channels for the offered shares, ensuring compliance with regulatory standards.
UBS, Bryan, Garnier & Co, Degroof Petercam, and KBC Securities are exclusively acting on behalf of the Company in connection with the Private Placement. They do not consider any other parties as clients in this context. This exclusivity highlights the importance of understanding client relationships and the associated responsibilities in financial transactions, particularly in private placements where regulatory scrutiny is heightened.
Forward-looking statements are inherently risky and may diverge significantly from anticipated results due to various factors such as regulatory approval delays, shifts in market demand, competitive pressures, and technological advancements. Stakeholders should approach these statements with caution as they do not guarantee future performance. The company explicitly states that it is not obligated to update or revise forward-looking statements based on changes in expectations or circumstances. This serves as a reminder of the volatile nature of financial markets and the unpredictability of investment outcomes. Investors should not overly rely on these statements as they reflect conditions only as of the date of the communication.
The offering of securities is subject to strict jurisdictional restrictions, particularly in regions such as the United States, Canada, Australia, and Japan. The document clarifies that it does not constitute an offer to sell or a solicitation to buy securities in these jurisdictions where such actions may be unlawful. The securities in question have not been registered under the U.S. Securities Act of 1933, and there will be no public offering in the United States.
In the European Economic Area, the document is classified as an advertisement rather than a prospectus, in accordance with Regulation (EU) 2017/1129. No public offering requiring a prospectus will be made in any Member State, and the securities will only be offered to qualified investors as defined by the Prospectus Regulation. This careful delineation of legal parameters is essential for maintaining compliance and protecting both the issuer and potential investors from legal repercussions.
The announcement also mentions various ONWARD Medical devices and therapies, including ARC-IM®, ARC-EX®, ARC-BCI™, and ARC Therapy™. These are currently classified as experimental and not available for commercial use. This distinction highlights the ongoing research and development phase of these medical technologies, which may eventually have broader applications in the healthcare sector.
The communication emphasizes that these devices are not yet commercially viable, underscoring the importance of regulatory approvals and clinical trials in bringing innovative medical solutions to market. Investors interested in the healthcare sector should be aware of the unique challenges and timelines associated with medical device development, which can significantly differ from traditional investment opportunities in other sectors.